Regencell Bioscience Holdings Limited Cash and Cash Equivalents
Regencell Bioscience Holdings Limited (RGC) had Cash and Cash Equivalents of $6.42 million as of 2022-06-30, per its 20-F filed 2022-10-31.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2022-10-31
- 2022-06-30: Cash and Cash Equivalents, at Carrying Value $6.42M.
- 2021-06-30: Cash and Cash Equivalents, at Carrying Value $59.41K.
- 2020-06-30: Cash and Cash Equivalents, at Carrying Value $386.98K.
- 2019-06-30: Cash and Cash Equivalents, at Carrying Value $243.31K.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2022-06-30 | $6.42M 20-F · filed 2022-10-31 |
| 2021-06-30 | $59.41K 20-F · filed 2022-10-31 |
| 2020-06-30 | $386.98K 20-F · filed 2021-10-29 |
| 2019-06-30 | $243.31K 20-F · filed 2021-10-29 |
| 2018-06-30 | $153.30K 20-F · filed 2021-10-29 |